Ahead of National Custodian Day, RCP will host 11 appreciation events nationwide, recognizing more than 1,250 custodial and facility maintenance professionals whose work helps keep communities running every day

- Rubbermaid Commercial Products (RCP) is celebrating the fifth year of the Behind the Scenes of Clean initiative ahead of National Custodian Day on October 2, recognizing the professionals who help keep facilities operating every day.

- As the centerpiece of the initiative, RCP is hosting 11 recognition events in cities across the country, celebrating an estimated 1,250 custodial and facility maintenance professionals.

- Through the initiative, RCP is elevating the often-unseen work of custodial teams and reaffirming its commitment to equipping them with solutions designed to support their day-to-day work.

HUNTERSVILLE, N.C., Sept. 29, 2026 /PRNewswire/ -- Rubbermaid Commercial Products® (RCP), part of the Newell Brands portfolio, today announced the return of the Behind the Scenes of Clean initiative, a nationwide appreciation program honoring custodians, cleaning professionals and facility teams ahead of National Custodian Day on October 2. Now in its fifth year, the initiative recognizes the people whose work helps keep workplaces, healthcare facilities, public spaces, hospitality venues, transportation hubs and entertainment destinations operating every day. This year, RCP will host 11 appreciation events nationwide, personally recognizing around 1,250 custodial and facility professionals for their contributions to communities across the country.

Launched in 2022, Behind the Scenes of Clean has become an annual tradition that celebrates the custodial and facility professionals whose work is essential to keeping communities running. Since its inception, the initiative has hosted more than 250 recognition events nationwide and honored around 25,000 custodial and facility maintenance professionals, celebrating the often-unseen workforce behind clean, safe, and welcoming environments.

"Behind the Scenes of Clean has grown into a meaningful tradition of gratitude," said Robert Posthauer, President, Commercial Segment of Newell Brands. "Behind every workplace, school, hospital, and public space are dedicated professionals whose contributions are often unseen, but always essential. We are proud to celebrate the people whose hard work helps communities function every day and to thank them in person for the impact they make."

How RCP Is Celebrating in 2026

As the centerpiece of this year's initiative, RCP will host 11 appreciation events across the country, recognizing around 1,250 custodial and facility professionals face-to-face. At each event, custodial and facility teams will be recognized through appreciation gatherings celebrating the often-unseen work that keeps facilities running every day. Events will take place in communities across the United States, including Mooresville, Atlanta, Orlando, Chicago, and Naples, where local teams will be recognized for their service and contributions.

RCP's Legacy of Innovation and Support

Supporting custodial professionals goes beyond recognition. For more than 55 years, RCP has helped custodians and facility teams succeed with durable, trusted products, from BRUTE® heavy-duty containers and HYGEN® microfiber cleaning systems to safety signage, washroom innovations, and foodservice solutions. Guided by its purpose, Made for Work That Matters, RCP delivers industry-leading products engineered to last longer, perform better, and help keep people safer. That commitment continues across the portfolio with innovations such as the next generation of BRUTE® containers and enhanced janitorial cleaning carts designed to help teams work more efficiently and confidently every day.

Join the Movement

Ahead of National Custodian Day on October 2, RCP encourages everyone to take a moment to thank a custodian, cleaning professional, or facility team member in their community. Whether through a personal note, workplace recognition, or a simple expression of gratitude, every gesture helps spotlight the essential professionals whose work often goes unseen. To learn more about Behind the Scenes of Clean and join the movement, visit rubbermaidcommercial.com/btsoc.

About Rubbermaid Commercial Products (RCP):

Rubbermaid Commercial Products LLC (RCP), headquartered in Huntersville, NC, has supported the people who make the world work since 1968. As a global leader in commercial and institutional solutions, RCP designs durable, innovative products across waste and recycling, material handling, cleaning, washroom, and safety categories—helping essential facilities like hospitals, schools, restaurants, warehouses, and commercial buildings stay clean, safe, and operational every day.

RCP is part of Newell Brands' global portfolio of leading brands and continues to develop innovative products. Visit www.rubbermaidcommercial.com, and join us on Facebook, Instagram, LinkedIn & X to learn more.

About Newell Brands:

Newell Brands (NASDAQ: NWL) is a leading global consumer goods company with a strong portfolio of well-known brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, DYMO, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. Newell Brands is focused on delighting consumers by lighting up everyday moments.

Media Contacts:

Alison Brod Marketing + Communications

[email protected] 

SOURCE Newell Brands

Share this article

More Than 20 Million Americans Have Loved Ones Whose Cremated Remains Have No Permanent Place to Be Remembered

National Cremation Placement Day will bring communities together October 17 to honor these lives and create lasting legacies.

COLD SPRING, Minn., Sept. 29, 2026 /PRNewswire/ -- More than 20 million family members and friends have loved ones whose cremated remains are kept in homes or passed down through generations without a permanent place to be remembered. Often, this is not due to a lack of care, but because families lack guidance, timing and support.

The first-ever National Cremation Placement Day will take place Saturday, October 17, 2026, creating a national opportunity to bring greater awareness to permanent placement and memorialization of cremated remains. Established and registered by Coldspring, the observance will take place annually on the third Saturday in October.

Created in recognition of the 150th anniversary of cremation in America, National Cremation Placement Day brings the memorialization community together to educate families about permanent placement, remembrance and the role these practices can play in creating a lasting legacy.

Funeral homes, cemeteries, monument dealers and industry partners are encouraged to participate by sharing information, hosting local observances and creating meaningful opportunities for families to gather and remember loved ones. Through education, remembrance and community connection, the initiative aims to:

- Increase awareness of permanent placement options

- Support healthy grief through shared remembrance

- Help families find relief from long-term uncertainty

- Prevent future mishandling or abandonment of cremated remains

National Cremation Placement Day will culminate in a single day when communities across the country can come together to celebrate the lives of those who have passed and create a lasting place of remembrance.

Coldspring has developed planning guides, promotional materials and community outreach tools to support participation nationwide. Resources are available through the National Cremation Placement Day Resources page.

About Coldspring

Coldspring is a leading quarrier and fabricator of natural stone and bronze serving the architectural, memorial, residential and industrial markets. Family owned and operated since 1898, the company is headquartered in Cold Spring, Minnesota, and employs more than 800 people across the country. Coldspring operates 30 quarries and multiple fabrication facilities and is committed to delivering innovative material solutions through teamwork, craftsmanship and a focus on corporate sustainability.

Media Contact

Susan Becker

[email protected]

320.685.4653

SOURCE Coldspring

Share this article

The Beef. It's What's For Dinner. brand is connecting cuisines and cultures from around the world in new video series.

DENVER, Sept. 29, 2026 /PRNewswire/ -- From birria to bolognese to bulgogi, beef has shaped some of the world's most iconic dishes – and now, you can explore how one ingredient connects cultures across the globe. The Beef. It's What's For Dinner. brand, funded by beef farmers and ranchers, is celebrating the flavors, traditions and creativity that make global cuisine so exciting with a new video series: One Ingredient, Endless Cultures.

This new video series takes viewers on a flavorful journey, highlighting classic beef dishes from around the world and showing how beef's versatility inspires endless culinary possibilities. Whether it's tucked into a sandwich, twirled into noodles or folded into a pastry, beef brings depth, comfort and character to every bite.

To make different parts of the world feel a little closer – the series spotlights three recipe categories that showcase beef's diversity: Beef Sandwiches, Beef & Noodles and Beef Pastries & Dumplings. Each category features a standout recipe that brings its cultural roots to life, featuring recipes such as:

- Beef French Dip with Au Jus: A classic American favorite, this savory sandwich layers tender beef on a toasted roll with warm, rich au jus for dipping. It's simple, comforting and endlessly satisfying.

- Bavarian Beef Schnitzel with Warm Tangy Slaw: Inspired by Germany's schnitzel‑and‑spaetzle tradition, this dish pairs crispy, golden beef schnitzel with a bright, tangy slaw for a balance of hearty and refreshing flavors.

- Asian-Style Beef Sausage Pot Stickers: Representing Japan's beloved gyoza, these pan‑seared dumplings are filled with savory beef and aromatics, delivering a perfect bite that's crisp on the bottom and tender inside.

For more recipes from this video series to inspire you to taste your way around the world, visit our One Ingredient, Endless Cultures page on BeefItsWhatsForDinner.com. You can also view the series on our Facebook and Instagram pages.

About the Beef Checkoff

The Beef Checkoff Program was established as part of the 1985 Farm Bill. The Checkoff assesses $1 per head on the sale of live domestic and imported cattle, in addition to a comparable assessment on imported beef and beef products. States may retain up to 50 cents on the dollar and forward the other 50 cents per head to the Cattlemen's Beef Promotion and Research Board, which administers the national checkoff program, subject to USDA approval.

About NCBA, a Contractor to the Beef Checkoff

The National Cattlemen's Beef Association (NCBA) is a contractor to the Beef Checkoff Program. The Beef Checkoff Program is administered by the Cattlemen's Beef Board, with oversight provided by the U.S. Department of Agriculture.

Contact: Hailey Thayn, [email protected]

SOURCE National Cattlemen's Beef Association

Share this article

In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity

Participants receiving Zepbound 15 mg had more than three times the odds of achieving at least 20% body-weight reduction compared with Wegovy HD

INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Foundayo (orforglipron), today announced results from a new analysis showing that Zepbound (tirzepatide) 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater weight loss than Wegovy HD (semaglutide injection 7.2 mg) in adults with obesity. The findings come from an indirect treatment comparison of Zepbound and Wegovy HD, drawing on data from the SURMOUNT-1 and STEP UP trials.1,2,3 These results, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, add to the growing body of evidence comparing Zepbound and Wegovy, including SURMOUNT-5, a randomized controlled Phase 3b trial in which Zepbound 10 mg and 15 mg demonstrated superior weight loss compared with Wegovy 1.7 mg and 2.4 mg.

"For people living with obesity, the choice of treatment matters, and clinicians increasingly want evidence on how the available options compare," said John Wilding, DM, professor of medicine at the University of Liverpool. "Tirzepatide 10 mg and 15 mg and semaglutide 1.7 mg and 2.4 mg were compared directly in SURMOUNT-5, where tirzepatide helped people with obesity lose more weight. In the absence of a head-to-head trial comparing tirzepatide 15 mg against semaglutide 7.2 mg, this indirect comparison offers useful evidence for physicians as they make treatment decisions."

In the indirect treatment comparison, which was covariate-adjusted for gender, age, baseline weight and baseline A1C, Zepbound 10 mg and 15 mg were associated with greater reductions in body weight than Wegovy HD at 72 weeks using the treatment-regimen estimand.4,5 Participants taking Zepbound 15 mg lost 4.5% more of their body weight (95.0% CrI: -6.3, -2.8) on average, and those taking 10 mg lost 3.2% more of their body weight (95.0% CrI: -5.0, -1.4). Using the efficacy estimand, Zepbound 15 mg and 10 mg were associated with 1.8% (95.0% CrI: -3.8, 0.1) and 0.7% (95.0% CrI: -2.6, 1.3) greater mean weight reduction than Wegovy HD, respectively, though these differences did not reach statistical significance.6

"People with obesity have more treatment options than ever before, and their healthcare providers deserve as much information as possible to help guide their decisions," said Thomas Seck, M.D., senior vice president of product development, Lilly Cardiometabolic Health. "In a head-to-head Phase 3 clinical trial, Zepbound 10 mg and 15 mg delivered greater weight loss than Wegovy 1.7 mg and 2.4 mg, and a new indirect treatment comparison suggests the same doses of Zepbound may outperform Wegovy HD, as well. Together, these results offer physicians more information as they choose a treatment path."

In addition to achieving greater weight loss, participants taking Zepbound 15 mg were four times more likely to achieve 20% or greater body weight reduction compared with Wegovy HD using the efficacy estimand (odds ratio 4.15; 95.0% CrI: 1.02, 15.64), and more than three times more likely using the treatment-regimen estimand (odds ratio 3.54; 95.0% CrI: 1.05, 11.05). While not statistically significant, participants taking Zepbound 10 mg had more than two times the odds of achieving at least 20% body-weight reduction compared with Wegovy HD using the efficacy (odds ratio 2.8; 95.0% CrI: 0.7, 10.8) and treatment-regimen estimands (odds ratio 2.46; 95.0% CrI: 0.7, 7.8).

Zepbound 10 mg and 15 mg showed comparable rates of treatment discontinuation due to adverse events versus Wegovy HD across both estimands.

About SURMOUNT-1 and the SURMOUNT clinical trial program  

SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S., Argentina, Brazil, China, India, Japan, Mexico, Russia and Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo. The co-primary objectives of the study were to demonstrate that tirzepatide 10 mg and/or 15 mg is superior in percentage of body weight reductions from baseline and percentage of participants achieving ≥5% body weight reduction at 72 weeks compared to placebo.

The SURMOUNT phase 3 global clinical development program for tirzepatide in chronic weight management began in late 2019 and has enrolled more than 5,000 people with obesity or overweight across six registration studies, four of which are global studies.

About SURMOUNT-5

SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes. Participants in both treatment groups received counseling on a reduced-calorie diet and increased physical activity. The trial randomized 751 participants across the U.S. and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of Zepbound (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg). With tirzepatide, 89.3% received at least one dose of the 15 mg dose and with semaglutide 92.8% received at least one dose of the 2.4 mg dose. The primary objective of the study was to demonstrate Zepbound's superiority in percent change from baseline in body weight at 72 weeks compared to Wegovy.

For the primary endpoint, participants treated with Zepbound achieved an average weight reduction of 20.2% compared to 13.7% with Wegovy at 72 weeks using the treatment-regimen estimand, a 47% greater relative weight loss. Participants using Zepbound lost an average of 50.3 lbs (22.8 kg) and participants on Wegovy lost an average of 33.1 lbs (15.0 kg).

About Zepbound (tirzepatide) injection

Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced calorie diet and increased physical activity.

Endnotes and References

- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.

- Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 2025; 13, 949-963. https://doi.org/10.1016/S2213-8587(25)00226-8

- Wilding J, Postma MJ, Jacobi D, et al. Tirzepatide 10 and 15 mg (SURMOUNT-1) vs semaglutide 7.2 mg (STEP UP) in adults with obesity without type 2 diabetes: an indirect treatment comparison. Presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD).

- Weight loss data represent an ML-NMR analysis.

- Treatment-regimen estimand represents the estimated average treatment effect regardless of treatment discontinuation.

- Efficacy estimand represents efficacy prior to discontinuation of study drug.

U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

- obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

- moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

- Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

- Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).

- Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

- Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems.

Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board

CALGARY, AB, Sept. 29, 2026 /PRNewswire/ -- Providence Therapeutics Holdings, Inc. is pleased to announce formation of its initial Clinical Advisory Board. This advisory group will help steer Providence's therapeutic mRNA cancer vaccine programs, including the Company's personalized vaccine program for pediatric brain cancer patients as well as the Company's off-the-shelf precision therapy vaccines for a range of solid tumor cancers.

Providence's Clinical Advisory Board will be chaired by the Company's Chief Medical Officer, Leon Rozen, MD. Joining Providence's Clinical Advisory Board are Ezra Cohen, MD; Melinda Merchant, MD, PhD; and John Powderly, MD.

Ezra Cohen is currently Chief Medical Officer for Oncology at Tempus AI. Dr. Cohen has been a medical oncologist with significant involvement in advancement of cancer immunotherapies. He was previously Professor of Medicine, Division Chief Hematology/Oncology and Associate Director at the Moores Cancer Center at the University of California, San Diego.

Melinda Merchant is a cancer immunotherapy drug developer and pediatric oncologist who served as Chief Medical Officer at Normunity and has held senior development roles at AstraZeneca, Epizyme, and Black Diamond Therapeutics. As a clinician and academic scientist, Dr. Merchant led multiple clinical trials at the National Cancer Institute (NCI) and Memorial Sloan Kettering Cancer Center, with direct experience advancing novel immunotherapies in high unmet need settings across both adult and pediatric cancers.

John Powderly MD is medical oncologist and President of the Carolina BioOncology Institute, where his roles include oversight of multiple early phase cancer clinical research trials. Dr. Powderly graduated from Georgetown School of Medicine, followed by additional training and research at US National Cancer Institute; University of Texas, Houston Health Science Center, MD Anderson Cancer Center; and University of North Carolina, Chapel Hill.

"We are excited to add Ezra, Melinda and John to Providence's extended team to help guide development of life-changing therapeutic vaccines as an important emerging treatment modality for cancer patients," commented Dr. Rozen.

About Providence Therapeutics:

Founded in 2015 with operations in the USA, Canada, and Australia, Providence Therapeutics is a clinical stage mRNA vaccine company with a proprietary mRNA lipid nanoparticle (LNP) platform that is designed to elicit superior antitumor effects.

Providence has multiple programs in oncology; foremost being PaedNEO-VAX, a national Phase 1/2 personalized cancer vaccine trail in Australia targeting Pediatric Brain Cancers.

For more information visit www.providencetherapeutics.com

SOURCE Providence Therapeutics Holdings Inc

Share this article

In honor of World Mental Health Day, Rula is launching "T(ask) for Help," covering new patients' everyday tasks to give more time to prioritizing mental health.

LOS ANGELES, Sept. 29, 2026 /PRNewswire/ -- Rula, a national behavioral healthcare provider delivering high quality, insurance-covered care, is partnering with Taskrabbit to launch "T(ask) for Help," in honor of World Mental Health Day – an initiative designed to address one of the practical barriers that keeps people from starting therapy: finding the time to actually do it.

The initiative is rooted in a startling fact: Nearly 50% of adults in need of mental support don't have the time or availability to seek care*. When people are already struggling, an overwhelming to-do list can make it even harder to prioritize mental health. To help move seeking care higher on that list, Rula is partnering with Taskrabbit to take one task off people's plates and give them back something everyone can use more of: time. Starting September 29 through World Mental Health Day on October 10, eligible new patients who book their first therapy session at Rula.com/taskforhelp will receive a $50 Taskrabbit credit to use towards help with an everyday task, creating more space to prioritize their mental health and take that first step toward care.

"Too often, taking care of our mental health becomes something we'll get to when we have the time," said Josh Bruno, CEO and Founder of Rula. "But with so many competing priorities, that time rarely creates itself. At Rula, we believe mental health care deserves a place on everyone's to-do list, and our partnership with Taskrabbit is about helping people create the space to take the important first step of getting started."

"You don't need a major home overhaul to feel a huge sense of relief. Sometimes just scratching one small thing off your list makes all the difference," said Tamara Rosenthal, SVP, Marketing at Taskrabbit. "Hanging a shelf or replacing a light fixture might seem small, but crossing off just one item gives you instant peace of mind. By partnering with Rula, we're making it easier to hand off that one lingering task so you have the time and mental energy to take care of yourself."

Launching ahead of World Mental Health Day on October 10, T(ask) for Help builds on Rula's national "Turn Off the Talk Track" campaign, which was built on research-backed insight that our own internal dialogue is often what stands in the way of seeking the mental health care we need. This new partnership brings one of those familiar thoughts to life: "I'll start therapy once I get everything else done."

Developed with creative and media agency Mischief @ No Fixed Address, the partnership and associated campaign assets underscore how Rula works to reduce both the emotional and practical barriers that can prevent people from accessing care. With a nationwide network of more than 22,000 licensed providers for therapy and psychiatry, Rula helps patients match with a provider in minutes, verify insurance coverage and out-of-pocket costs upfront, and schedule their first appointment as soon as the next day.

For more information about Rula's services, visit Rula.com or Rula's social channels on YouTube, Instagram, and LinkedIn.

About Rula

Rula is a comprehensive behavioral health solution that makes high-quality mental health care more accessible and affordable. With a nationwide network of more than 22,000 licensed providers, Rula offers next-day availability for therapy and psychiatry, 24/7 crisis support, and a seamless digital experience that connects patients to the right care quickly. Patients can match with a provider in minutes, verify insurance coverage and out-of-pocket costs upfront, attend secure telehealth sessions, and track their progress—all within a single, easy-to-use platform. Rula partners with most major insurance networks, including Aetna, Anthem, Cigna, Kaiser, United Healthcare, and most Blue Cross and Blue Shield plans, covering more than 200 million lives across the U.S. Learn more at Rula.com.

About Taskrabbit

Taskrabbit is a global digital platform that connects people seeking help with household tasks — such as Furniture Assembly, TV Mounting, Help Moving, and Home Improvements — to skilled, reliable Taskers in their communities. Acquired by the Ingka Group (IKEA) in 2017, Taskrabbit operates in thousands of cities across eight countries: Canada, France, Germany, Italy, Portugal, Spain, the United Kingdom, and the United States. Taskrabbit is also available in 240+ IKEA stores worldwide.

To find out more, please visit www.taskrabbit.com or join the conversation with @Taskrabbit on Instagram, TikTok, Facebook, X, LinkedIn, Pinterest, and YouTube.

* Source & Full Data: Substance Abuse & Mental Health Services Administration National Survey, 2025. 48.3% of adults with a mental illness who felt they needed treatment but did not receive it cited not having enough time for treatment as a reason they did not seek care.

Terms and Conditions: Offer valid only for new users who have not previously received services through Rula. Users must sign up through rula.com/taskforhelp to be eligible for this offer - standard signups through any other web URL are not eligible. Offer is not valid in Delaware, Florida, Texas, or North Carolina, or for users enrolled in federal or state healthcare programs, such as Medicare, Medicaid, Medicare Advantage, Managed Medicaid, and TRICARE/CHAMPUS. The $50 credits are redeemable only with Taskrabbit for services booked, and their use is subject to the Taskrabbit Global Terms of Service. Credit is not redeemable on Rula for therapy, psychiatry or any other offering. Limited to one $50 credit per user. Offer is valid for 60 days from the date of issuance and must be loaded to the user's Taskrabbit account; it is non-transferable, has no cash value, and cannot be redeemed for cash or cash equivalents. Users who successfully qualify will receive an email confirmation after their first appointment is scheduled, which will include their unique code and activation instructions.

SOURCE Rula Health

Share this article

Confidential Cook County birth injury settlement provides lifelong support for a child who sustained permanent damage to the right arm

CHICAGO, Sept. 29, 2026 /PRNewswire/ -- Zayed Law announced today that attorneys Adam J. Zayed and Julian D. Hoshell secured a $3.5 million settlement on behalf of a child who sustained Erb's palsy during birth. According to the Jury Verdict Reporter, the confidential settlement ties the Illinois state record for a settlement in this type of case prior to trial.

The lawsuit alleged that an obstetrician used excessive force and applied excessive lateral traction while addressing the shoulder dystocia during delivery. The newborn suffered a brachial plexus injury that caused permanent deformity, disfigurement, dysfunction, and limited use of the right arm.

The Cook County matter was resolved for $3.5 million, with $2.5 million contributed on behalf of the defendant hospital and $1 million contributed on behalf of the defendant obstetrician.

"This result reflects the life-changing consequences a preventable birth injury can have on a child and an entire family," said Adam J. Zayed, founder of Zayed Law. "No settlement can undo that harm, but this recovery will help provide access to care, therapy and support the child may need throughout life. We were honored to advocate for this family and secure a resolution that recognizes the seriousness of the injury."

Erb's palsy is a form of brachial plexus birth injury that can occur when the network of nerves controlling the shoulder, arm and hand is damaged. The severity and long-term effects vary, but affected children may experience weakness, loss of motion, impaired function, or permanent disability.

Because the settlement is confidential, the identities of the child, family, hospital and obstetrician will not be disclosed.

Zayed Law remains committed to advocate for individuals and families harmed by medical negligence and continues its work to advance accountability and improve patient care nationwide.

About Zayed Law

Zayed Law is a personal injury and medical malpractice law firm representing individuals and families in Illinois, Florida and nationwide. Founded by trial attorney Adam J. Zayed, the firm handles birth injury, medical malpractice, catastrophic injury, wrongful death and other complex cases. Zayed Law prepares every case with a trial-ready approach and is committed to helping clients pursue accountability and meaningful compensation.

Media Contact

Zayed Law

Dee Fritz

Director of Marketing

312.726.1616

www.zayedlawoffices.com

SOURCE Zayed Law

Share this article

New ETF Offers a Systematic Approach to International Country & Region Rotation Using the Momentum Factor

GLASTONBURY, Conn., Sept. 29, 2026 /PRNewswire/ -- Symmetry Partners ("Symmetry"), a leading investment manager, today launched the Symmetry Panoramic International Country Momentum ETF (Ticker: ICMO), designed to provide investors with systematic exposure to international countries and regions demonstrating strong relative momentum.

ICMO is grounded in a dynamic, rules-based strategy that uses cross-sectional momentum to seek long-term capital appreciation by investing in the international countries and regions of the MSCI ACWI ex-US universe that have the strongest relative performance.

With returns of the top 13 performing countries over the last 15 years (through 8/2026)1 averaging almost 27% annually, a strategy focused on trying to identify the best performing countries exhibiting positive momentum offers the potential for enhanced returns.

Symmetry's new ETF combines robust, research-backed momentum signals with a disciplined rebalancing approach to capture evolving international trends. The strategy allocates 75% of the portfolio to the highest-performing countries, based on 6- and 12-month momentum signals, and 25% of the portfolio to 1 of 3 international regions, International Developed, Emerging Markets, or the Total International Market, again based on momentum signals.

As International and Emerging Markets have demonstrated strong performance in recent years, ICMO may provide Financial Advisors and investors with a compelling solution for international diversification* and potential return enhancement. ICMO can , be used in place of or as a supplement to a traditional International core allocation, act as an active- strategy replacement, or enhance a factor-tilted portfolio.

"ICMO demonstrates our continued commitment to providing innovative, rules-based solutions," said David Connelly, CEO of Symmetry Partners. "We believe this ETF delivers a distinctive way to capture changing leadership in international markets and is a wonderful complement to the Symmetry Panoramic Sector Momentum ETF (Ticker: SMOM) launched in September 2025."

Symmetry Partners is known for its evidence-based investment approach and suite of solutions designed to help financial advisors better serve their clients. The launch of ICMO further expands the firm's investment lineup, reflecting growing demand for factor-driven, dynamic investment options.

1 Morningstar Direct, as of 8/25/2026. Based on MSCI Indices *Diversification does not ensure a profit or guarantee against a loss.

About Symmetry

Symmetry Partners is a SEC registered investment advisor based in Glastonbury, CT, which has created an ecosystem of investment products and advisory services to support financial advisors.

Media Contact

Matthew Hamel, Executive Vice President, Sales & Distribution [email protected] 860.734.2007

CAREFULLY CONSIDER THE FUND'S INVESTMENT OBJECTIVES, RISK FACTORS, CHARGES, AND EXPENSES BEFORE INVESTING. THIS AND ADDITIONAL INFORMATION CAN BE FOUND IN THE FUND'S FULL OR SUMMARY PROPECTUS, WHICH CAN BE OBTAINED BY VISITING WWW.PANORAMICFUNDS.COM OR BY CALLING 1-844-SYM-FUND (844-796-3863). PLEASE READ THE PROSPECTUS CAREFULLY BEFORE INVESTING.

There are risks involved in investing, including loss of principal. Asset allocation may not protect against market risk. Shares of ETFs are not individually redeemable directly with the ETF. Shares of ETFs are bought and sold at market price, which may be higher or lower than the net asset value (NAV).

Symmetry Partners, LLC serves as an investment adviser to Symmetry Funds. The funds are distributed by SEI Investment Distribution Co. (SIDCO), which is not affiliated with Symmetry Partners, LLC, or Vident Asset Management.

Principal Investment Risks: As with all exchange-traded funds, there is the risk that you could lose money through your investment in the Fund. A Fund share is not a bank deposit and it is not insured or guaranteed by the FDIC or any other government agency. Other principal risks include, but not limited to: Market Risk; ETF Risks; Equity Risk; Geographic Focus Risk; Foreign Investment Risk; Large-, Mid-, Small- Capitalization Companies Risk; Foreign Currency Risk; Index Tracking Error Risk; Depositary Receipts Risk; Asset Allocation Risk; Operational Risk; Liquidity Risk; Valuation Risk; High Portfolio Turnover Risk. International and Emerging Markets Risk; Momentum Style Risk; Quantitative Investing Risk; Non-Diversified Risk; Active Management Risk

MSCI ACWI ex USA NR USD: A broad global equity index representing large-and mid-cap companies across developed and emerging markets excluding the United States. The index reflects the net total return, assuming dividends are reinvested after applicable withholding taxes, and is denominated in U.S. dollars.

Cross-Sectional Momentum - A method that ranks a set of assets against one another by recent return strength.

SOURCE Symmetry Partners

Share this article

- Large-scale exploration footprint: The authorization covers six properties totaling 59,895 hectares, representing approximately 25% and the largest component of the entire Laguna Salada Project.

TORONTO, Sept. 29, 2026 /PRNewswire/ -- Jaguar Uranium Corp. (NYSE American: JAGU) ("Jaguar" or the "Company") is pleased to announce that it has received approval of the Environmental Impact Assessment ("EIA") for the "La Rosada" prospect area from the Ministry of Environment of the Province of Chubut. This critical permit covers the La Rosada prospect, a key component of the Company's flagship Laguna Salada uranium exploration project in Argentina.

Laguna Salada is a district-scale uranium-vanadium exploration project comprising approximately 230,000 hectares in Argentina. The newly permitted La Rosada prospect is situated 45 kilometers northeast of the Guanaco prospect, which received its own EIA approval earlier this year (see news release dated March 2, 2026).

The permit officially authorizes exploration activities across six properties at the La Rosada prospect, encompassing a total of 59,895.3 hectares – approximately 25% of the entire Laguna Salada project:

Upcoming Exploration Program

With EIA approval secured, Jaguar is fully authorized to commence prospecting activities immediately following the conclusion of the winter season, including a planned multi-faceted work program involving:

- Systematic geochemical sampling and detailed geological mapping.

- Comprehensive radiometric grid surveys.

- Electrical resistivity tomography designed to identify and assess deep fluvial paleochannels.

"Approval of the EIA marks an important milestone for Jaguar Uranium," said Steven Gold, Chief Executive Officer of Jaguar Uranium Corp. "Given the scale of the Laguna Salada project, this approval advances our exploration strategy and positions the Company to move efficiently into the next phase of fieldwork."

About Jaguar Uranium Corp.

Jaguar Uranium Corp. is a South America-focused uranium exploration company advancing a portfolio of prospective brownfield projects across Colombia and Argentina. The Company's Berlin Project in Caldas Province, Colombia is a district-scale, sedimentary-hosted polymetallic system historically reported to host uranium vanadium, nickel, phosphate, molybdenum, rhenium and zinc. In Argentina, Jaguar is advancing the Laguna Salada Project in Chubut Province and the historic Huemul uranium mine in Mendoza Province. Anchored by a former producing mine, a historic uranium district and exploration projects supported by historical drilling, the Company is focused on advancing and expanding uranium opportunities across the region.

Qualified Person

The scientific and technical information disclosed in this news release has been reviewed and approved by C. Gustavo Fernandez, P. Geo., a consultant to the Company, who is a Qualified Person under National Instrument 43-101 – Standards of Disclosure for Mineral Projects and Subpart 1300 of Regulation S-K.

Website: www.jaguaruranium.com

Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to statements about Laguna Salada's exploration and development potential, the Company's ability to ramp up exploration activity at the Laguna Salada Project, the Company's ability to utilize its cash and the anticipated effects thereof, and the Company's ability to revive and expand its uranium opportunities. These forward-looking statements are based on a number of material factors and assumptions, including the execution of planned exploration activities, the availability of required personnel, equipment, permits and property access, the application of the Company's funds as budgeted, and management's internal planning parameters relating to timing, costs, commodity prices and foreign exchange rates. Each forward-looking statement involves a number of risks, uncertainties or other factors that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those discussed and identified in public filings made by the Company with the Securities and Exchange Commission.

Any statements in this press release that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as "anticipate", "is anticipated", "expects", "is expected", "believes", "is believed", "plans", "projects", "estimates", "assumes", "intends", "strategy", "goals", "objectives", "potential", "positions", "possible" or variations thereof or stating that certain actions, events, conditions or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved (or the negative of any of these terms and similar expressions) are not statements of fact and may be forward-looking statements.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, investors should not place undue reliance on forward-looking statements contained in this press release or in certain of the other documents on file with Canadian securities regulatory authorities, which are available on the Company's SEDAR+ profile at www.sedarplus.ca. The Company and its directors, officers and employees each disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable law. Accordingly, investors should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investors should read this press release with the understanding that the Company's actual future results may be materially different from what is expected.

These forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Jaguar Uranium

Share this article

2027 Notes and 2028 Term Loan maturities to be extended to 2031

CHARLOTTE, N.C., Sept. 29, 2026 /PRNewswire/ -- JELD-WEN Holding, Inc. (NYSE: JELD) ("JELD-WEN" or the "Company") today announced it has entered into a commitment and consent letter with a significant group of its lenders and noteholders to address its near-term debt maturities and strengthen the Company's capital structure. Under the agreement, JELD-WEN expects to extend the maturities of its 4.875% Senior Notes due 2027 (the "2027 Notes") and its 2028 term loans (the "2028 Term Loans") to 2031 and raise $135 million of new money debt financing. The agreement secures additional capital and maturity runway to support the Company's operations and business plan.

The commitment and consent letter collectively represents approximately 94.5% of the 2027 Notes and approximately 72.2% of the 2028 Term Loans, pursuant to which the parties have agreed to consummate a series of transactions (the "Transactions") that will refinance and/or exchange the Company's existing 2027 Notes and 2028 Term Loans for new first lien debt maturing in 2031 and raise $135 million of new money debt financing. In the coming weeks, the Company intends to commence certain exchange offers to holders of the 2027 Notes and 2028 Term Loans to implement the Transactions.

"Addressing our near-term maturities and strengthening our balance sheet have been key priorities for JELD-WEN," said Chief Executive Officer William J. Christensen. "This agreement is an important step forward. It extends our 2027 Notes and 2028 Term Loans maturities to 2031, brings additional capital into the business and gives us greater financial flexibility as we continue to execute our plan. Our focus remains unchanged: serving our customers, improving productivity, reducing costs and managing cash with discipline. We believe this transaction provides a stronger foundation to continue that work."

Kirkland & Ellis LLP is acting as legal counsel to JELD-WEN, and Evercore Group L.L.C. is serving as financial advisor to JELD-WEN. Davis Polk & Wardwell LLP and Houlihan Lokey Capital, Inc. are acting as legal and financial advisors to certain holders of 2027 Notes. Gibson, Dunn & Crutcher LLP and Moelis & Company LLC are acting as legal and financial advisors to certain lenders of 2028 Term Loans.

About JELD-WEN Holding, Inc.

JELD-WEN Holding, Inc. (NYSE: JELD) is a leading global designer, manufacturer and distributor of high-performance interior and exterior doors, windows, and related building products serving the new construction and repair and remodeling sectors. Based in Charlotte, North Carolina, JELD-WEN operates facilities in 14 countries in North America and Europe and employs approximately 13,900 associates dedicated to bringing beauty and security to the spaces that touch our lives. The JELD-WEN family of brands includes JELD-WEN® worldwide, LaCantina® and VPI™ in North America, and Swedoor® and DANA® in Europe. For more information, visit corporate.JELD-WEN.com or follow us on LinkedIn.

Investor Relations Contact:

James Armstrong

Vice President, Investor Relations

704-378-5731

[email protected]

Media Contact:

JELD-WEN Holding, Inc.

Sarah Bruner

Senior Director, Enterprise Communications

980-403-4459

[email protected]

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are generally identified by our use of forward-looking terminology, including the terms "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "seek," or "should," and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts are forward-looking statements, including statements about the consummation of the Transactions and the expected benefits therefrom, our business strategies and ability to execute on our plans, market potential, future financial performance and our expectations, beliefs, plans, objectives, prospects, assumptions, or other future events, all of which involve risks and uncertainties that could cause actual results to differ materially. We have based these forward-looking statements on our current expectations, assumptions, estimates, and projections. While we believe these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. Such factors include, but are not limited to, our ability to consummate the Transactions; our ability to execute and realize the expected benefits of the Transactions; the impact of the Transactions on the market price of our securities; litigation, including the outcome of any legal proceedings that may be instituted against us or others relating to the Transactions; diversion of management's attention away from our business on account of the Transactions; our ability to raise additional capital in the future; the risk that an insufficient number of eligible participants participate in the Transactions; our ability to obtain the support and consent of the lenders under our asset-based revolving credit facility to participate in the Transactions; if the Transactions are not consummated, the potential delays and significant costs of alternative transactions, which may not be available to us on acceptable terms, or at all, which in turn may impact our ability to continue as a going concern; the adverse impact of failing to consummate the Transactions or otherwise deleveraging on our financial condition, business prospects and the market price of our securities; and the factors disclosed in our filings with the U.S. Securities and Exchange Commission from time to time, including, without limitation, those factors described in our Annual Report on Form 10-K for the year ended December 31, 2025 and the Quarterly Reports on Form 10-Q filed in 2026.

The forward-looking statements included in this release are made as of the date hereof, and we undertake no duty or obligation to update or revise these forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

No Offer or Solicitation

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction in connection with the Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this press release is not an offer of securities for sale into the United States.

SOURCE JELD-WEN Holding, Inc.

Share this article